Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Scorr-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Pierre Fabre

              • Development Update

              Virtual BoothThe 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group.

              FRANCE France

              Contact Supplier Contact Supplier

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              Pierre Fabre receives Positive CHMP Opinion for BRAFTOVI® in Combination with Cetuximab for Treatment of BRAFV600E-mutant Colorectal Cancer

              Contact the Supplier

              Lead Product(s): Encorafenib,Cetuximab

              Therapeutic Area: Oncology

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 01, 2020

              Details:

              Phase 3 BEACON CRC trial data showed that BRAFTOVI in combination with cetuximab significantly improved overall survival in patients with BRAFV600E-mutant mCRC and reduced the risk of death by 40%.

              Sanofi

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              FRANCE France

              Contact Supplier Contact Supplier

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              CHMP backs Sanofi’s myeloma drug Sarclisa

              Contact the Supplier

              Lead Product(s): Isatuximab,Pomalidomide,Dexamethasone

              Therapeutic Area: Oncology

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 27, 2020

              Details:

              Positive CHMP opinion based on data from ICARIA-MM, the first randomized Phase 3 trial to evaluate an anti-CD38 in combination with pom-dex.

              Onxeo

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              FRANCE France

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              Onxeo to Receive $6.6 Million by Granting Additional Exclusive Rights to Belinostat to Acrotech Biopharma LLC

              Contact the Supplier

              Lead Product(s): Belinostat

              Therapeutic Area: Oncology

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Acrotech Biopharma

              Deal Size: $6.6 million Upfront Cash: $6.6 million

              Deal Type: Agreement April 06, 2020

              Details:

              The new Agreement grants Acrotech a royalty-free license to belinostat in all other territories including the United States, Canada, Mexico, and India.

              PharmaCompass__DigitalAd